| Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 | 09/25 16:30 | globenewswire.com |
| Cabaletta Bio to Participate in Upcoming Investor Conferences in September | 08/28 08:00 | globenewswire.com |
| Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update | 08/08 07:00 | globenewswire.com |
| Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum | 07/02 08:00 | globenewswire.com |
| Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment | 06/28 13:42 | seekingalpha.com |
| Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 | 06/14 02:00 | globenewswire.com |
| Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update | 05/15 07:00 | globenewswire.com |
| Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ | 05/13 08:00 | globenewswire.com |
| Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 03/21 07:00 | globenewswire.com |
| Cabaletta Bio to Participate in Upcoming Investor Conferences in March | 02/27 08:00 | globenewswire.com |